Drugs / AON-D21
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05343819 | Apr → Nov 2022 | — | Aptarion Biotech AG | Completed | No outcome recorded |
| Phase 1 | NCT05018403 | Aug 2021 → Jan 2022 | — | Aptarion Biotech AG | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05962606 | Feb 2024 → Mar 2026 | pneumonia | Aptarion Biotech AG | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AON-D21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05343819 ↗ |
| Action | Inhibit | “neutralizes the complement component C5a from activating both C5a receptors” NCT05018403 ↗ |
| Modality | Aptamer | “AON-D21 is a Pegylated L-configured aptamer” NCT05018403 ↗ |
| Route | Intravenous | “single ascending intravenous doses of AON-D21” NCT05018403 ↗ |